The use of Bifidobacteria to support or treat diverticulitis has some scientific basis, though the evidence is not robust. The rationale stems from the general understanding that probiotics, including Bifidobacteria species, may help modulate gut microbiota, reduce inflammation, and support intestinal barrier function. Several clinical studies have evaluated probiotics for diverticular disease (which includes both diverticulosis and diverticulitis) and found some benefit in symptom management and reduction of recurrence, although these studies often use mixed probiotic strains and not Bifidobacteria alone or in unspecified forms.

A few small clinical trials and reviews have noted that probiotic supplementation, particularly combinations that include Bifidobacteria, may decrease abdominal symptoms and inflammation in patients with diverticular disease. However, high-quality randomized controlled trials focusing specifically on Bifidobacteria (unspecified) for acute diverticulitis are lacking. Most available studies have methodological limitations, such as small sample sizes, heterogeneous probiotic formulations, and varying outcome measures. Major clinical guidelines do not currently recommend probiotics as a standard treatment for diverticulitis, reflecting the low to moderate quality of evidence.

In summary, while there is some scientific rationale and preliminary evidence for the use of Bifidobacteria-containing probiotics in diverticular disease, the data are insufficient to strongly support their use specifically for diverticulitis, and further research is needed.